Plain-English translation of NCT05629546 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a combination of three treatments for advanced melanoma that has grown despite standard immunotherapy: special immune cells called memory-like natural killer cells, plus two immunotherapy drugs called and relatlimab. The study wants to learn whether this combination is safe and whether it can help shrink tumors in patients whose melanoma has progressed on checkpoint inhibitor therapy.
Many patients with advanced melanoma stop responding to the standard immunotherapy drugs available today, and their cancer continues to grow. Researchers believe that adding specially prepared immune cells to the standard treatments might help fight the cancer more effectively in these patients.
You likely qualify if…
You likely don't qualify if…
On Day 0, you will receive an infusion of the special immune cells. Depending on which arm you're in, these cells will come either from your own body (if you're in Arm 1, after a collection procedure) or from a matched donor (if you're in Arm 2). Starting on Day 29, you will receive infusions of the two immunotherapy drugs every 28 days for up to 11 cycles (about 11 months), unless your cancer progresses, you experience severe side effects, or you and your doctor decide to stop earlier. You will have regular blood tests and scans to monitor how the treatment is working.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States